Company Profile
Cerevel Stock Price, News & Catalysts
- Ticker:
- CERE
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Why the stock is moving
Current closing-price context is not available for CERE.
Company overview
Business overview
Cerevel Therapeutics was a neuroscience biotech focused on receptor pharmacology and CNS drug development before being acquired by AbbVie.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ prior to acquisition, it sat in CNS biotechnology.
Business Model Characteristics
The story was built around clinical-stage psychiatry and neurology programs, with valuation tied to pipeline data and strategic interest.
Position Within the Biotechnology Landscape
Cerevel was a high-quality neuroscience catalyst name and now belongs to biotech M&A history.
Future catalysts
- Cerevel’s near-term catalyst is mostly transaction resolution and any final closeout / integration-related milestone tied to the company’s acquired pipeline assets. The next update will help show whether the company is moving from promise to a more de-risked stage of execution. Investors will care less about the label than about whether the platform can keep producing credible next steps.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What does Cerevel do?
Cerevel Therapeutics was a neuroscience biotech focused on receptor pharmacology and CNS drug development before being acquired by AbbVie.
On which exchange is CERE stock listed?
Cerevel (CERE) is associated with NASDAQ, United States, Biopharma.
What is Cerevel?
Cerevel’s near-term catalyst is mostly transaction resolution and any final closeout / integration-related milestone tied to the company’s acquired pipeline assets.
Which conditions is Cerevel targeting with Cerevel?
Cerevel is associated with neuroscience based on its company overview and current catalyst commentary.
How does Cerevel describe recent progress with Cerevel?
Cerevel’s near-term catalyst is mostly transaction resolution and any final closeout / integration-related milestone tied to the company’s acquired pipeline assets.
What is Therapeutics?
Cerevel Therapeutics was a neuroscience biotech focused on receptor pharmacology and CNS drug development before being acquired by AbbVie.
What should investors watch for with Therapeutics?
Cerevel’s near-term catalyst is mostly transaction resolution and any final closeout / integration-related milestone tied to the company’s acquired pipeline assets. The next update will help show whether the company is moving from promise to a more de-risked stage of execution. Investors will care less about the label...
What is AbbVie?
Cerevel Therapeutics was a neuroscience biotech focused on receptor pharmacology and CNS drug development before being acquired by AbbVie.